Wegovy Novo Nordisk warns of workers’ layoffs with competition growth | Business and Economics News

Novo Nordsk The outgoing CEO and Less Fergard Yorgensen, He has warned that the demobilization of workers in the Danish pharmaceutical giant can be inevitable, as it heats the competition against the amazing obesity medicine in Yigovi amid the increasing pressure from its rival Eli Lily.

Novo Nordisk – which has become the most 650 billion dollar companies in Europe, faced last year for the prosperity of Wegovy sales – a pivotal moment as medicine loses the market share and sees the growth growth slowly, especially in the United States.

He has been warned of the slower growth this year, partly due to the two compounds that were allowed to make Copycat medications based on the same ingredients as Wegovy due to the shortage. Novo Nordisk, which contains 77,000 employees on the web, reduced its sales throughout the year and its profits last week, giving 95 billion dollars in its market value since then.

The slide is a vast and sudden transformation of the company, which was one of the most important investment stories in the world, which led to the rapid expansion of manufacturing and sales. Now the company is looking for possible measures to reduce costs.

Limbing workers waving

“Perhaps we will not be able to avoid the demobilization of workers,” Georgessen told the Danish broadcaster. “When you have to control a company, there are some areas where there should be fewer people, and some areas (you should be smaller.”

He added, though, that any decision on demobilization will be in the hands of the incoming CEO, veteran Mike Mike Doustdar, who is responsible on Thursday.

In a media call, JorgenSen said that the Wegov Fielding Verses market of drugs-known as GLP-1 receptors-was “equal to our business”, and vehicle versions of Wegov were sold with “much lower price point”.

In May, Novo Nordisk said she expects that many million American patients who use GLP-1 compound drugs to switch to brand treatments after the US Food and Drug Administration Prohibit a vehicle From Wegovy valid on May 22, and expected to end in the third quarter.

However, Finance Coastan Monc Knodsen said on Wednesday that more than a million American patients are still using the compound GLP-1 and that the company’s low expectations “did not assume a decrease in doubling” this year.

“The obesity market is volatile.” He said that the low side of the new direction for the entire year is “unexpected events”, such as the most powerful pricing in the United States.

The minimum range of the range means sales of about 150 billion Danish kronor (23 billion dollars) in the second half of 2025, compared to 157 billion kronor (24.5 billion dollars) in the same period last year.

Knudsen repeated that the company was following multiple strategies, including lawsuits against the guaranteed pharmacies, to stop illegal collective complications.

Georgessen said that the company had encouraged the latest prescription data in Wagofi. While the medicine was exceeded earlier this year by its rival Eli Lilis, in terms of American prescriptions, this introduction was narrowed last month.

Novo Nordisk said the Wegovy sales in the second quarter increased by 36 percent in the United States and more than a quadruple in the markets outside the United States compared to a year ago.

Knudsen said that although the prices of Wegov in the United States are fixed in the quarter, the company expected deeper erosion in the main American market in the second half, due to the presence of a larger part of the expected sales of the direct channel of the consumer or cash, as well as high discounts and discounts to insurance companies.

He said that Novo Nordisk was expanding its direct platform for consumers, which was launched in March, and you may need to follow “cash sales” similar directly to patients, outside insurance channels, in some markets outside the United States.

Cost discounts

Novo Nordisk repeated the perception of the entire year’s profits on Wednesday after the profit warning last week.

Georgessen said that the company was working to “ensure efficiency at our cost base”, as it announced that it would finish eight research and development projects.

“It seems that there is more cleaning and development than usual, but we do not know if this reflects a strategic reassessment or just a coincidence,” Jeffrez analysts said in a note.

Investors wondered whether the company could be able to compete in the prosperous weight loss market. Several stock analysts have reduced their prices and recommendations on stocks since last week.

The shares in Novo Nordisk fell 30 percent last week – the worst weekly performance in more than two decades. The stock has continued to falter since the opening of the market in New York. As of 12 pm local time (16:00 GMT), the drug giant decreased by more than 3.3 percent.